These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 37018872)
1. A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system. Coolbrandt A; Tobback H; Govaerts R; Vandezande L; Vinckx M; Laenen A; Wildiers H; Verslype C; Dekervel J; Van Herpe F; Van Cutsem E ESMO Open; 2023 Apr; 8(2):101205. PubMed ID: 37018872 [TBL] [Abstract][Full Text] [Related]
2. Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer. Coolbrandt A; Vancoille K; Dejaeger E; Peeters H; Laenen A; Neven P; Punie K; Wildiers H Breast Cancer Res Treat; 2022 Apr; 192(2):293-301. PubMed ID: 34982322 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup. Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448 [TBL] [Abstract][Full Text] [Related]
4. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro). Gehr NL; Karlsson P; Timm S; Christensen S; Hvid CA; Peric J; Hansen TF; Lauritzen L; Finnerup NB; Ventzel L BMC Cancer; 2024 Feb; 24(1):168. PubMed ID: 38308227 [TBL] [Abstract][Full Text] [Related]
5. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial. Kerckhove N; Tougeron D; Lepage C; Pezet D; Le Malicot K; Pelkowski M; Pereira B; Balayssac D BMC Cancer; 2022 Jul; 22(1):742. PubMed ID: 35799138 [TBL] [Abstract][Full Text] [Related]
7. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial. Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of the Motivational Interviewing-Walk Intervention for Chemotherapy-Induced Peripheral Neuropathy and Quality of Life During Oxaliplatin Treatment: A Pilot Randomized Controlled Trial. Kanzawa-Lee GA; Ploutz-Snyder RJ; Larson JL; Krauss JC; Resnicow K; Lavoie Smith EM Cancer Nurs; 2022 Mar-Apr 01; 45(2):E531-E544. PubMed ID: 34483279 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial. Rokhsareh S; Haghighi S; Tavakoli-Ardakani M J Oncol Pharm Pract; 2023 Jan; 29(1):60-65. PubMed ID: 34738855 [TBL] [Abstract][Full Text] [Related]
10. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients. Hines RB; Schoborg C; Sumner T; Zhu X; Elgin EA; Zhang S Support Care Cancer; 2023 Jun; 31(7):386. PubMed ID: 37294347 [TBL] [Abstract][Full Text] [Related]
11. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study. Oh PJ; Lee JR; Kim SK; Kim JH Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847 [TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer. Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660 [TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life. Stefansson M; Nygren P Acta Oncol; 2016; 55(9-10):1227-1235. PubMed ID: 27550718 [TBL] [Abstract][Full Text] [Related]
14. Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2). Miura Y; Ando M; Yamazaki K; Hironaka S; Boku N; Muro K; Hyodo I Support Care Cancer; 2021 Jul; 29(7):3715-3723. PubMed ID: 33200233 [TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment. Kang L; Tian Y; Xu S; Chen H J Neurol; 2021 Sep; 268(9):3269-3282. PubMed ID: 32474658 [TBL] [Abstract][Full Text] [Related]
16. Prophylactic efficacy of ninjin'yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2). Motoo Y; Tomita Y; Fujita H Int J Clin Oncol; 2020 Jun; 25(6):1123-1129. PubMed ID: 32232692 [TBL] [Abstract][Full Text] [Related]
17. Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparison. Johnson K; Stoffel B; Schwitter M; Hayoz S; Rojas Mora A; Fischer Maranta A; El Saadany T; Hasler U; von Moos R; Patzen A; Mark M; Roberts G; Cathomas R Support Care Cancer; 2024 Jul; 32(8):554. PubMed ID: 39066890 [TBL] [Abstract][Full Text] [Related]
18. Renin-Angiotensin-Aldosterone System Inhibitors Prevent the Onset of Oxaliplatin-Induced Peripheral Neuropathy: A Retrospective Multicenter Study and in Vitro Evaluation. Uchida M; Ushio S; Niimura T; Takechi K; Kawazoe H; Hidaka N; Tanaka A; Araki H; Zamami Y; Ishizawa K; Kitamura Y; Sendou T; Kawasaki H; Namba H; Shibata K; Tanaka M; Takatori S Biol Pharm Bull; 2022 Feb; 45(2):226-234. PubMed ID: 34803077 [TBL] [Abstract][Full Text] [Related]
19. Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin. Yildirim N; Cengiz M Support Care Cancer; 2020 Oct; 28(10):4781-4788. PubMed ID: 31974772 [TBL] [Abstract][Full Text] [Related]
20. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702. Lee S; Ma C; Shi Q; Kumar P; Couture F; Kuebler P; Krishnamurthi S; Lewis D; Tan B; Goldberg RM; Venook A; Blanke C; O'Reilly EM; Shields AF; Meyerhardt JA J Clin Oncol; 2023 Feb; 41(5):1079-1091. PubMed ID: 36367997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]